Skip to content


Event Information:


June 22 and 23, 2023

Boston MA, United States, TransCure presenting virtually

Related Models & Services

CD34+ Humanized Mouse
Immuno-Oncology Models

Join us at the 6th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference 2023

We are pleased to announce our virtual participation in the 6th annual MarketsandMarkets Next-Gen Immuno-Oncology Conference. This prestigious event, to be held on June 22 and 23, 2023 in Boston, will focus on the challenges and future directions of immuno-oncology (IO) research.

The event will bring together academics, researchers and scientists from research institutes, pharmaceutical and biotech companies to discuss the latest updates in the development of ADCs (antibody-drug conjugates), bispecific antibodies, cell therapy and immune checkpoint inhibitors. By focusing on these cutting-edge advances, we strive to advance the field of IO research.

Conference highlights include updates on the development of ADCs and bispecific antibodies, the exploration of biomarkers and personalized medicine in IO, as well as insights into the tumor microenvironment and oncolytic viruses. These topics offer invaluable opportunities for knowledge sharing and networking with industry experts.

We look forward to welcoming you to our conference and collaborating at the forefront of immuno-oncology research! Stay tuned for further updates!

Why participate?

New Case Studies: This event is an opportunity to keep abreast of new developments in antibodies, cell therapy and immune checkpoint research, the latest developments and case studies in immuno-oncology projects, and ongoing research.
Interactive roundtables: Participate in interactive roundtables with your peers, discussing the key topics that interest you most.

Cutting-edge technologies: Explore the latest platforms and technologies available on the market for development and research purposes.

New encounters: CSOs, directors, vice-presidents, chiefs, principal investigators, managers, senior scientists, team leaders, group leaders, professors, assistant professors, research fellows and PhDs working in the fields of monoclonal and bispecific antibodies, cell therapy and immune checkpoint inhibitors to attend this conference.

To register and learn more about the event, please visit the official webpage and for further information, don’t hesitate to contact us:

Dan GeorgessAttending virtually for TransCure bioServices:

Dan Georgess, PhD, Director of Alliance Management

Dan Georgess is an experienced scientist, team leader and project manager. He is dedicated to promoting cross-functional efforts to overcome outstanding challenges in therapeutics development. He joined TransCure as Project Leader and now oversees the Alliance Management Team. Through his Marie Curie Ph.D. training at ENS de Lyon, Suzan G. Komen postdoctoral fellowship at the Johns Hopkins School of Medicine, and his tenure-track leadership of the Cancer Invasion and Metastasis Cluster at the Lebanese American University, Dan has developed cutting-edge ex vivo and in vivo platforms and co-authored 15 peer-reviewed publications.

This event has concluded